XML 61 R44.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue- Narrative (Details)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 102 Months Ended
May 28, 2021
USD ($)
Aug. 03, 2020
USD ($)
shares
Jan. 07, 2018
USD ($)
Oct. 31, 2014
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2020
USD ($)
Mar. 31, 2023
USD ($)
Oct. 01, 2014
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Expenses related to collaboration agreement         $ 114,766,000 $ 131,076,000 $ 365,636,000 $ 390,391,000        
Income tax expense         0 254,000 0 254,000        
Unrealized gain (loss) on available-for-sale investments         106,000 (1,000) 2,175,000 (5,712,000)        
Total revenue         16,400,000 5,431,000 37,257,000 11,502,000        
Cost of product revenue         1,428,000 0 3,011,000 0        
Product Revenue                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Total revenue         16,400,000 0 36,056,000 0        
Milestone Payments                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Expenses related to collaboration agreement           0   0        
BeiGene Agreement                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Non-refundable, non-creditable up-front fee     $ 10,000,000                  
Milestone payments     $ 123,000,000                  
Termination of contract, period after first commercial sale of product     10 years                  
Period required for notice of termination of contract     60 days                  
Performance obligation, compensation to be earned                   $ 500,000    
Milestone payments earned         0 0 0 0        
Royalty revenue         0 0 0 0        
BeiGene Agreement | Maximum                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Royalty percentage rate (up to)     0.20                  
BeiGene Agreement | Licenses of Intellectual Property                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Performance obligation, compensation to be earned     $ 9,500,000                  
BeiGene Agreement | Manufacturing Supply Services                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Revenue recognized         0 0 0 0        
Pfizer Agreement                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Termination of contract, period after first commercial sale of product       10 years                
Period required for notice of termination of contract       60 days                
Pfizer Agreement | Development Milestone Payments                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Potential development milestone payments                       $ 9,300,000
Development milestone payments         0   1,000,000       $ 10,500,000  
Pfizer Agreement | Sales Milestone Payments                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Potential development milestone payments                       $ 337,000,000
Pfizer Agreement | Milestone Payments - First Commercial Sale of KRAZATI                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Potential development milestone payments         15,000,000   15,000,000          
Pfizer Agreement | Royalties                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Cost of product revenue         1,200,000   2,600,000          
ORIC Pharmaceuticals Agreement                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Stock received as part of stock issuance and license agreements (shares) | shares   588,235                    
License agreement, period of transfer restrictions   18 months                    
License agreement, period of agreement after first commercial sale   10 years                    
ORIC Pharmaceuticals Agreement | Level 3                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
One-time non-cash payment   $ 11,400,000                    
Zai Agreement                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Period required for notice of termination of contract 12 months                      
Milestone payments earned         0 5,000,000 0 5,000,000        
Termination of contract, period after first commercial sale of product 10 years                      
Up-front fee received $ 65,000,000                      
Transaction price of arrangement 66,600,000                      
Zai Agreement | Licenses of Intellectual Property                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Revenue recognized                 $ 66,600,000      
Income tax expense                 $ 3,300,000      
Zai Agreement | Manufacturing Supply Services                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Revenue recognized         0 300,000 1,200,000 1,400,000        
Zai Agreement | Milestone Payments                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Milestone payments earned               5,000,000        
Zai Agreement | Sales Milestone Payments                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Revenue from performance obligation expected to be earned 180,000,000                      
Zai Agreement | Development and Regulatory Milestone Payments                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Revenue from performance obligation expected to be earned $ 93,000,000                      
Zai Agreement | Royalties                        
Research and Development Arrangement, Contract to Perform for Others [Line Items]                        
Royalty revenue         $ 0 $ 0 $ 0 $ 0